Drug intelligence / Profile preview

paracetamol + aminopyrine + caffeine + chlorpheniramine maleate

Development stage
Unknown
Lead developer
Sinopharm Xingsha
Modality
Small Molecules
Administration
Oral
01

Overview

Phenamine Caffeine Tablets (酚氨咖敏片) is a multi-ingredient oral OTC medication manufactured by Sinopharm Xingsha Pharmaceuticals (Xiamen) for the symptomatic relief of the common cold, fever, headache, and neuralgia. The combination consists of four active pharmaceutical ingredients: **paracetamol** and **aminopyrine**, which serve as antipyretics and analgesics by inhibiting cyclooxygenase (COX) enzymes and reducing prostaglandin synthesis; **caffeine**, a central nervous system stimulant that enhances the analgesic effect and counteracts drowsiness; and **chlorpheniramine maleate**, an H1-receptor antagonist that alleviates allergic-like symptoms such as rhinorrhea, sneezing, and watery eyes. This formulation is a standard generic product in the Chinese consumer health market for rapid relief of upper respiratory infection symptoms.

Brand names
Phenamine Caffeine Tablets
Other names
酚氨咖敏片Fen An Ka Min Pianphenamine caffeine tablets
02

Targets

ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)

Beyond the preview

Go deeper on paracetamol + aminopyrine + caffeine + chlorpheniramine maleate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + aminopyrine + caffeine + chlorpheniramine maleate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call